In order to improve cutting-edge knowledge on Rare Hematological Diseases (RHD), ERN-EuroBloodNet has identified across Europe the healthcare areas including highly specialized procedures requiring preceptorship for the acquisition of medical expertise. First interventional healthcare area identified is: Inherited and acquired bone marrow failures including Aplastic Anaemia (AA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) in adult and pediatric patients.
ERN-EuroBloodNet is endorsing three preceptorships held in ERN-EuroBloodNet highly specialized centers for AA and PNH with the objective to provide applicants with the fundamental tools for a correct diagnostic and treatment approach to bone marrow failures, including AA and PNH in children, adolescents and adult patients.
The highly specialized centers hosting the preceptorships are ERN-EuroBloodNet members that represent the excellence in RHD field at International level. This call for participant is already full, more information on other disease programs will come soon.
From 13/01/2020 to 16/01/2020 (4 days)
Host Center: AP-HP, Hôpital Saint-Louis, Paris, France
Coordinated by: Prof Regis Peffault de la Tour
From 03/02/2020 to 5/02/2020 (3 days)
Host Center: Federico II University of Naples, Italy
Coordinated by: Prof. Antonio Risitano
From 17/02/2020 to 20/02/2020 (4 days)
Coordinated by: Dr. Carlo Dufour
The Preceptorship program for AA and PNH is already full with a total of 14 Participants from 8 Member States attending to:
Congratulations to all!
Are you willing to benefit for EuroBloodNet Preceptorship programs? Stay tuned! More information on other disease programs will come soon!
EuroBloodNet Association is in charge to cover the costs for travel and accommodation of participants. EuroBloodNet Association will also provide for costs of daily stay and it will support logistic and arrangements for the educational material and it will be in charge of costs of logistic and arrangement site organization.
Preceptorship on AA and PNH are partially supported by EuroBloodNet Association through a Grant received from Alexion Pharma France.